by winston » Thu Sep 13, 2018 10:56 am
not vested
WEIGAO GROUP(1066)
Analysis:
At the beginning of the year, Shandong Weigao Group Medical Polymer (1066) optimized its product strategies, reclassified from former single-use consumables, hemodialysis business and orthopedic business into eight business segments, comprising clinical nursing care, wound management, blood management, pharma packaging, medical testing, anesthesia and surgical related products, orthopedics and interventional products.
These segments cover an enormous size of market.
For the six months ended 30 June 2018, the revenue of the Group was RMB4.15 billion, representing an increase of 3 9.4% over the same period last year.
Turnover of high value-added products (with a gross profit margin of over 60%) accounted for 61.7% (same period last year: 57.9%) of the total turnover.
Excluding extraordinary items, net profit attributable to shareholders was RMB762 million, representing an increase of 17.2% when compared with the same period last year. (I do not hold the above stock)
Strategy:
Buy-in Price: $7.30, Target Price: $8.00, Cut Loss Price: $6.90
Source: Phillips
It's all about "how much you made when you were right" & "how little you lost when you were wrong"